Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Zepzelca

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 15, 2020

            Details:

            PharmaMar and Jazz Pharma have entered into an amended and restated license agreement of the US lurbinectedin license agreement signed in December 2019 for the purpose of granting Jazz an exclusive license for Zepzelca™ (lurbinectedin) in Canada.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trabectedin

            Therapeutic Area: Oncology Product Name: Yondelis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Onko Kocsel Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 10, 2020

            Details:

            Trabectedin is currently provided by Janssen to patients in Turkey for the treatment of Soft Tissue Sarcoma and, through this license, Onko will also pursue regulatory approval for the indication of relapsed ovarian cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trabectedin,Doxorubicin HCl,Dexamethasone

            Therapeutic Area: Oncology Product Name: Yondelis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 24, 2020

            Details:

            EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of a study that investigated Yondelis as a third-line treatment in patients with ovarian cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: PM1183

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            This filing is based on data from the phase II monotherapy basket trial with lurbinectedin for the treatment of SCLC. lurbinectedin demonstrated an Overall Response Rate (ORR) of 35 percent and a median Duration of Response (DoR) of 5.3 month.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trabectedin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Key Oncologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 19, 2020

            Details:

            PharmaMar will retain exclusive production rights for Yondelis®(trabectedin), which will be sold to Key Oncologics for its clinical and commercial use in South Africa, Namibia and Botswana.